Australia markets closed
  • ALL ORDS

    7,320.70
    +8.70 (+0.12%)
     
  • ASX 200

    7,060.70
    +5.30 (+0.08%)
     
  • AUD/USD

    0.7736
    +0.0029 (+0.38%)
     
  • OIL

    61.76
    +0.33 (+0.54%)
     
  • GOLD

    1,788.20
    +6.20 (+0.35%)
     
  • BTC-AUD

    63,842.09
    -6,784.38 (-9.61%)
     
  • CMC Crypto 200

    1,134.08
    -108.97 (-8.77%)
     
  • AUD/EUR

    0.6415
    +0.0007 (+0.11%)
     
  • AUD/NZD

    1.0780
    +0.0024 (+0.23%)
     
  • NZX 50

    12,650.64
    +73.16 (+0.58%)
     
  • NASDAQ

    13,762.36
    -172.79 (-1.24%)
     
  • FTSE

    6,906.76
    -31.48 (-0.45%)
     
  • Dow Jones

    33,815.90
    -321.41 (-0.94%)
     
  • DAX

    15,272.86
    -47.66 (-0.31%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     

Former Montana Governor Steve Bullock to Monitor Purdue’s Compliance With Voluntary Injunction

·3-min read

Purdue Pharma L.P. ("Purdue") today announced the appointment of former Montana Governor Steve Bullock as Monitor to report quarterly to the Bankruptcy Court and Purdue’s board on the company’s compliance with its voluntary injunction. Gov. Bullock will have unfettered access to Purdue’s employees, books, records and facilities.

"We will provide our full cooperation to Gov. Bullock," said Purdue CEO Dr. Craig Landau. "In the last few years, we have made significant changes to our leadership, operations, governance, and oversight. As part of this commitment, we agreed to be bound by – and comply fully with – an unprecedented voluntary injunction that further restricts the Company’s promotion of its opioid medications."

In early 2018, Purdue ended all promotion of opioids to healthcare professionals through sales representatives and eliminated its opioid sales force. In its initial bankruptcy filings in 2019, Purdue voluntarily proposed to formalize its commitment to refrain from promoting its opioids through a voluntary injunction, and immediately acceded to the Court’s suggestion of a monitor.

Gov. Bullock succeeds United States Secretary of Agriculture and former Iowa Governor Tom Vilsack in the role of Monitor. During his time as Monitor, Secretary Vilsack filed four reports and, in each report, determined that the company continued to make good faith efforts to comply with the terms of the voluntary injunction.

Gov. Bullock served as the Governor of Montana from 2013 to 2021, during which he was Chair of the National Governors Association (2018-2019) and Chair of the Western Governors Association (2016-2017). Prior to serving as Governor, he was Attorney General of Montana from 2009-2013, during which time he worked to curb prescription drug abuse, pioneered the successful Montana 24/7 Sobriety Program, and created The Montana Children's Justice Center to protect the state’s children. Gov. Bullock resides in Helena, Montana with his wife and three children.

About Purdue Pharma L.P.

Purdue Pharma and its subsidiaries are physician-founded and physician-led companies that develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers. Purdue Pharma is also committed to driving innovations in patient care while continuing our efforts to address the opioid crisis.

Purdue’s subsidiaries include: Adlon Therapeutics L.P., focused on treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders; Avrio Health L.P., a consumer wellness company that provides over-the-counter products to fight infection, promote digestive wellness and provide health supplements; Imbrium Therapeutics L.P., established to develop and commercialize non-opioid pain medications and therapies for select oncology and CNS disorders; Rhodes Pharmaceuticals L.P., which develops and supplies primarily solid oral-dose and transdermal medications; and Greenfield Bioventures L.P., an investment vehicle focused on compounds in the early stages of clinical development.

For more information, visit www.purduepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301006077/en/

Contacts

Media:
Michele Sharp
michele.sharp@pharma.com
(203) 585-3195